Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors

Trial Profile

A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Head and neck cancer; Male breast cancer; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-012
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 28 Jan 2019 Planned End Date changed from 17 Jan 2019 to 17 Jan 2020.
    • 31 Aug 2018 Biomarkers information updated
    • 29 Jun 2018 Results (N=192) of advanced head and neck squamous cell carcinoma (HNSCC) cohorts with data cut-off date 26 April, 2016 published in the British Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top